Who are fluorouracil based chemotherapy regimens's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Fluorouracil 0.5%, Placebo plus S1, Phthalin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluorouracil-based-chemotherapy-regimens.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

fluorouracil based chemotherapy regimens — Competitive Intelligence Brief

fluorouracil based chemotherapy regimens (fluorouracil based chemotherapy regimens) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pyrimidine analog. Area: Oncology.

phase 3 pyrimidine analog thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

fluorouracil based chemotherapy regimens (fluorouracil based chemotherapy regimens) — China Medical University, China. Fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fluorouracil based chemotherapy regimens TARGET	fluorouracil based chemotherapy regimens	China Medical University, China	phase 3	pyrimidine analog	thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Fluorouracil 0.5%	Fluorouracil 0.5%	Wake Forest University	marketed	Antimetabolite, pyrimidine analog	Thymidylate synthase; RNA and DNA incorporation
Placebo plus S1	Placebo plus S1	Chinese PLA General Hospital	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase, dihydropyrimidine dehydrogenase
Phthalin	PHENOLPHTHALEIN		marketed	phenolphthalein	Thymidylate synthase, Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pyrimidine analog class)

AstraZeneca · 1 drug in this class
China Medical University, China · 1 drug in this class
Grupo Espanol de Tumores Neuroendocrinos · 1 drug in this class
Japan Clinical Oncology Group · 1 drug in this class
Servicio de Salud Metropolitano Sur Oriente · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fluorouracil based chemotherapy regimens — Competitive Intelligence Brief. https://druglandscape.com/ci/fluorouracil-based-chemotherapy-regimens. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab